CMC – Page 21 – Pharma.Tips

Prototype not scalable during early development – how to redesign formulation strategy

Strategies for Redesigning Formulation to Address Scalability Issues in Early Development In pharmaceutical research and drug development, early-stage formulators often encounter the challenge of prototypes that are not scalable. This…

Formulation fails stability targets during tech transfer – regulatory expectations for formulation data

Managing Stability Failures in Formulation During Technical Transfer In the context of pharmaceutical development, achieving and maintaining stability targets during tech transfer is critical for regulatory compliance and product reliability.…

Excipient incompatibility identified late during tech transfer – preventing late-stage reformulation

Strategies to Address Late-Stage Excipient Incompatibility During Tech Transfer In the dynamic landscape of pharmaceutical formulation, late-stage excipient incompatibility can pose significant challenges during tech transfers. Such incompatibilities often remain…

Excipient incompatibility identified late during IND/NDA filing – CMC risk assessment and mitigation

Managing Excipient Incompatibility Issues During IND/NDA Submissions Excipient incompatibility identified late during IND/NDA filing can pose significant risks to the successful registration and market launch of pharmaceutical products. These challenges…

Bioavailability risk flagged during tech transfer – CMC risk assessment and mitigation

Mitigating Bioavailability Risk During Tech Transfer: A Practical Playbook The transfer of technology in pharmaceutical manufacturing, particularly during formulation development, often brings to the forefront several risks. Chief among these…

Prototype not scalable during early development – regulatory expectations for formulation data

Tackling Scalability Challenges in Early Development: Regulatory Insights for Formulation Data Navigating the complexities of formulation development requires a strategic approach, especially when prototypes prove not scalable during early development…

Prototype not scalable during early development – regulatory expectations for formulation data

Strategies for Addressing Scale-Up Issues in Early Formulation Development In pharmaceutical development, encountering a prototype that is not scalable poses significant risks, particularly during the critical transition from formulation development…

Excipient incompatibility identified late during early development – preventing late-stage reformulation

Addressing Late-Stage Excipient Incompatibility in Early Development to Avoid Reformulation Challenges In pharmaceutical manufacturing, identifying excipient incompatibility during the early development stages is crucial for successful formulation development. Late detection…

Dissolution variability unexplained during tech transfer – preventing late-stage reformulation

Addressing Unexplained Dissolution Variability During Tech Transfer Dissolution variability during tech transfer poses significant challenges for pharmaceutical companies, particularly when faced with late-stage reformulation. These variances can stem from numerous…

Tag: CMC

Prototype not scalable during early development – how to redesign formulation strategy

Formulation fails stability targets during tech transfer – regulatory expectations for formulation data

Excipient incompatibility identified late during tech transfer – preventing late-stage reformulation

Excipient incompatibility identified late during IND/NDA filing – CMC risk assessment and mitigation

Bioavailability risk flagged during tech transfer – CMC risk assessment and mitigation

Prototype not scalable during early development – regulatory expectations for formulation data

Prototype not scalable during early development – regulatory expectations for formulation data

Excipient incompatibility identified late during early development – preventing late-stage reformulation

Dissolution variability unexplained during tech transfer – preventing late-stage reformulation

Formulation fails stability targets during IND/NDA filing – regulatory expectations for formulation data

QbD elements missing during IND/NDA filing – CMC risk assessment and mitigation

Bioavailability risk flagged during scale-up preparation – CMC risk assessment and mitigation